To include your compound in the COVID-19 Resource Center, submit it here.

FDA panel rebuffs Actavis' nebivolol/valsartan

FDA's Cardiovascular and Renal Drugs advisory committee voted 6-4 against approval of an

Read the full 133 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE